Feng Lin
Chief Tech/Sci/R&D Officer chez THERAPEUTIC SOLUTIONS INTERNATIONAL, INC.
Fortune : 50 000 $ au 31/03/2024
Profil
Feng Lin is currently the Chief Scientific Officer at Therapeutic Solutions International, Inc. He previously worked as the Director of Chinese Operations at Medistem, Inc. from 2012 to 2014, Senior Scientist at Inovio Pharmaceuticals, Inc. from 2007 to 2012, and Associate at Sanford Burnham Prebys Medical Discovery Institute from 1999 to 2005.
He was also the Chief Scientific Officer at SuperView Biotechnology Co. Ltd.
from 2014 to 2019.
Dr. Lin has a doctorate degree from Central South University, which he received in 1998, as well as a graduate degree and an undergraduate degree from the same university, which he received in 1994 and 1990, respectively.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2022 | 50 000 000 ( 1,30% ) | 50 000 $ | 31/03/2024 |
Postes actifs de Feng Lin
| Sociétés | Poste | Début |
|---|---|---|
| THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. | Chief Tech/Sci/R&D Officer | 03/09/2019 |
Anciens postes connus de Feng Lin
| Sociétés | Poste | Fin |
|---|---|---|
| SuperView Biotechnology Co. Ltd. | Chief Tech/Sci/R&D Officer | 01/08/2019 |
| MEDISTEM INC | Corporate Officer/Principal | 01/05/2014 |
| INOVIO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/11/2012 |
Sanford Burnham Prebys Medical Discovery Institute
 Sanford Burnham Prebys Medical Discovery Institute Medical/Nursing ServicesHealth Services Sanford Burnham Prebys Medical Discovery Institute conducts and translates biological research programs. The firm offers tumor initiation and maintenance, cancer metabolism and signaling network, tumor microenvironment and cancer immunology, degenerative disease, development/aging/regeneration, immunity and pathogenesis, human genetic, cardiovascular metabolism, integrative metabolism, metabolism genomic control, bioinformatics and structural biology programs. The company was founded by William Fishman and Lillian Fishman in 1976 and is headquartered in La Jolla, CA. | Corporate Officer/Principal | 01/12/2005 |
| RIVULET MEDIA, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Feng Lin
| Central South University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| INOVIO PHARMACEUTICALS, INC. | Health Technology |
| RIVULET MEDIA, INC. | Technology Services |
| ENTEST GROUP, INC. | Finance |
| THERAPEUTIC SOLUTIONS INTERNATIONAL, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Medistem, Inc.
 Medistem, Inc. Medical SpecialtiesHealth Technology Medistem, Inc. is focused on developing therapies for treating serious diseases and conditions using the natural regenerative properties of stem cells. Endometrial Regenerative Cell possess specialized abilities to stimulate new blood vessel growth and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. The company was founded by Neil H. Riordan in October 2005, and is headquartered in San Diego, CA. | Health Technology |
Sanford Burnham Prebys Medical Discovery Institute
Sanford Burnham Prebys Medical Discovery Institute Medical/Nursing ServicesHealth Services Sanford Burnham Prebys Medical Discovery Institute conducts and translates biological research programs. The firm offers tumor initiation and maintenance, cancer metabolism and signaling network, tumor microenvironment and cancer immunology, degenerative disease, development/aging/regeneration, immunity and pathogenesis, human genetic, cardiovascular metabolism, integrative metabolism, metabolism genomic control, bioinformatics and structural biology programs. The company was founded by William Fishman and Lillian Fishman in 1976 and is headquartered in La Jolla, CA. | Health Services |
| SuperView Biotechnology Co. Ltd. |
